- Sanofi, Pfizer join roster of pharmas marshalling relief for Turkey and Syria after deadly quake (fiercepharma.com)
As rescue efforts continue in the wake of a cataclysmic earthquake on the border of Turkey and Syria, drugmakers near and far are rushing to offer aid...Novartis and its generics arm Sandoz are putting up $1 million for the cause. At present, the companies are working to identify the right partners to “make sure this support gets to those most in need,”...Novartis also said it's in close contact with its local team to ensure the well-being of some 1,600 staffers and their families in the region...Bayer...will donate a total of 1.5 million euros to the affected regions...READ MORE
- HHS lays out timing for drug price negotiations (biopharmadive.com)
The agency will kick off discussions on how it will negotiate Medicare drug prices in the spring and publish the first 10 drugs selected by Sept. 1, 2023...The U.S. Department of Health and Human Services...released its timeline for negotiating prices on an initial tranche of Medicare drugs, a new power granted the agency by last year’s Inflation Reduction Act...Under the law, Medicare can negotiate prices for top-selling drugs that have no competition, starting with 10 in 2026 and rising to a total of 60 by 2029. But the law didn’t fully detail the process by which that will happen...READ MORE
- Brand-Name Drug Prices Fell for the Fifth Consecutive Year—And Plummeted After Adjusting for Inflation (drugchannels.net)
Time for the Drug Channels annual reality check on drug pricing. The data once again tell a different story than you might read in your favorite politician’s Twitter feed or misleading news reports...For 2022, brand-name drugs’ net prices dropped for an unprecedented fifth consecutive year. What’s more, after adjusting for overall inflation, brand-name drug net prices plunged by almost 9%...The factors behind declining drug prices will remain in the coming years—and become even stronger due to forthcoming changes in Medicare and Medicaid. Employers, health plans, and PBMs will determine whether patients will share in this ongoing deflation...READ MORE
- Millionaire pharma exec Gigi Jordan — who killed 8-year-old son — found dead inside NYC home in possible suicide (msn.com)Killer mom may be released from prison after conviction tossed (nypost.com)
Gigi Jordan, the millionaire pharmaceutical executive convicted of manslaughter in the death of her 8-year-old son, was found dead inside her Brooklyn home in what cops are investigating as a possible suicide...Her body was found around 12:30 a.m. Friday... just hours after US Supreme Court Justice Sonia Sotomayor issued an order that was expected to send Jordan, 62, back to prison...Jordan was accused of force-feeding her autistic son, Jude Mirra, a lethal dose of pills in February 2010...READ MORE
- States Move to Ban Accumulators (drugtopics.com)The State of Employers’ Pharmacy Benefits: A Review of 2022 and the 2023 Outlook for Copay Programs (drugchannels.net)How Copay Accumulators and Maximizers Have Changed Payers’ View of Copay Support (drugchannels.net)
Sixteen states have banned a pharmacy benefit management practice that involves not counting the value of drug copay assistance from manufacturers toward patient deductibles...Drugmakers use copay assistance programs to shield patients from out-of-pocket expenses — and build market share for their products in the process. But pharmacy benefit managers have cried foul, saying the copay programs undercut formularies and wind up increasing the use of expensive drugs that are not any better than less expensive ones. They have pushed back with “copay adjustment programs,” especially “copay accumulators,” which are designed to blunt the effect of the copay assistance programs by not counting their value toward patient deductibles...READ MORE
- California files suit against PBMs over insulin prices (healthcaredive.com)
California is suing major drug manufacturers and pharmacy benefits managers for allegedly leveraging their market power to overcharge patients for insulin...The state filed suit...against drug manufacturers Eli Lilly, Novo Nordisk, and Sanofi, along with major PBMs CVS Caremark, Cigna’s Express Scripts and UnitedHealth Group’s OptumRx...The lawsuit alleges that the drugmakers and PBMs worked together to drive up the price of insulin through illegal and deceptive business practices in violation of California’s Unfair Competition Law...READ MORE
- U.S. new drug price exceeds $200,000 median in 2022 (reuters.com)
After setting record-high U.S. prices in the first half of 2022, drugmakers continued to launch medicines at high prices in the second half, a Reuters analysis has found, highlighting their power despite new legislation to lower costs for older prescription products...The median annual price of the 17 novel drugs the U.S. Food and Drug Administration approved since July 2022 is $193,900, down from $257,000 in the first half of 2022...For full year 2022, the median was $222,003...The latest numbers imply double digit year-over-year price growth...READ MORE
- How a Drug Company Made $114 Billion by Gaming the U.S. Patent System (dnyuz.com)AbbVie’s global bestseller to face knockoffs starting this week (msn.com)
In 2016, a blockbuster drug called Humira was poised to become a lot less valuable...Through its savvy but legal exploitation of the U.S. patent system, Humira’s manufacturer, AbbVie, blocked competitors from entering the market. For the next six years, the drug’s price kept rising. Today, Humira is the most lucrative franchise in pharmaceutical history...Next week, the curtain is expected to come down on a monopoly that has generated $114 billion in revenue for AbbVie just since the end of 2016. The knockoff drug that regulators authorized more than six years ago, Amgen’s Amjevita, will come to market in the United States, and as many as nine more Humira competitors will follow this year from pharmaceutical giants including Pfizer. Prices are likely to tumble...READ MORE
- Union blasts staffing levels at HCA hospitals in Nevada, nationwide (8newsnow.com)
A union report that blasts “systemic low staffing” at HCA hospitals nationwide says that staffing levels at HCA’s Nevada hospitals is 34% lower than the national average...That’s putting patients in danger, the union said...Nationwide, HCA hospitals are staffed 30% below the national average, the report said. The report is based on Centers for Medicare and Medicaid Services data released in 2021...Now, nurses are calling on HCA to raise staffing levels, improve pay and prioritize higher-quality patient care...READ MORE
- China reopens borders in final farewell to zero-COVID (reuters.com)
Travellers began streaming into mainland China by air, land and sea on Sunday, many eager for long-awaited reunions, as Beijing opened borders that have been all but shut since the start of the COVID-19 pandemic...After three years, mainland China opened sea and land crossings with Hong Kong and ended a requirement for incoming travellers to quarantine, dismantling a final pillar of a zero-COVID policy that had shielded China's people from the virus but also cut them off from the rest of the world...READ MORE